Clinical considerations for the management of androgen indifferent prostate cancer.
Clinical considerations for the management of androgen indifferent prostate cancer.
复制标题
雄激素无关前列腺癌治疗的临床考虑。
DOI：
10.1038/s41391-021-00332-5
复制
发表时间：
2021-09
影响因子：
4.8
通讯作者：
Aparicio A
中科院分区：
文献类型：
--
作者：
Berchuck JE;Viscuse PV;Beltran H;Aparicio A
许多晚期前列腺癌的全身治疗通过破坏雄激素受体信号传导起作用。雄激素无关性前列腺癌（AIPC）变体，包括侵袭性变体前列腺癌（AVPC）、神经内分泌前列腺癌（NEPC）和双阴性前列腺癌（DNPC），在转移性去势抵抗性前列腺癌男性中使用雄激素受体信号传导抑制剂治疗后越来越常见，并且通常重叠耐药表型，并且与不良结局相关。了解潜在的生物学和确定AIPC的有效疗法对于改善前列腺癌患者的生存至关重要。在这篇综述中，我们总结了目前的知识AIPC变异，包括我们目前的理解的临床，形态学和分子特征，以及目前的治疗方法。我们还探索了旨在改善AIPC男性患者结局的新兴疗法和生物标志物。建立共识定义，开发用于早期和准确检测的新型生物标志物，进一步表征每种表型的分子驱动因素，以及开发有效的治疗方法对于改善AIPC男性患者的结局至关重要。在确定AVPC、NEPC和DNPC的临床和分子特征方面取得了重大进展。新的诊断方法，包括游离DNA，循环肿瘤细胞和分子成像是有前途的工具，用于检测AIPC在临床实践中。在以前治疗进展的基础上，正在进行几项临床试验，通过了解变异特异性生物学，评估AIPC患者的新治疗方法。在这篇综述中，我们讨论了这些最近和正在进行的研究将如何帮助改善诊断，预后和男性AIPC的治疗。
Many systemic therapies for advanced prostate cancer work by disrupting androgen receptor signaling. Androgen indifferent prostate cancer (AIPC) variants, including aggressive variant prostate cancer (AVPC), neuroendocrine prostate cancer (NEPC), and double negative prostate cancer (DNPC), are increasingly common and often overlapping resistance phenotypes following treatment with androgen receptor signaling inhibitors in men with metastatic castration-resistant prostate cancer and are associated with poor outcomes. Understanding the underlying biology and identifying effective therapies for AIPC is paramount for improving survival for men with prostate cancer. In this review, we summarize the current knowledge on AIPC variants, including our current understanding of the clinical, morphologic, and molecular features as well as current therapeutic approaches. We also explore emerging therapies and biomarkers aimed at improving outcomes for men with AIPC. Establishing consensus definitions, developing novel biomarkers for early and accurate detection, further characterization of molecular drivers of each phenotype, and developing effective therapies will be critical to improving outcomes for men with AIPC. Significant progress has been made towards defining the clinical and molecular characteristics of AVPC, NEPC, and DNPC. Novel diagnostic approaches, including cell-free DNA, circulating tumor cells, and molecular imaging are promising tools for detecting AIPC in clinical practice. Building on previous treatment advances, several clinical trials are underway evaluating novel therapeutic approaches in patients with AIPC informed by an understanding of variant-specific biology. In this review, we discuss how these recent and ongoing studies will help to improve diagnosis, prognosis, and therapy for men with AIPC.
登录
查看更多内容
影响因子：
21.3
作者：
通讯作者：
--
影响因子：
82.9
作者：
Beltran H;Prandi D;Mosquera JM;Benelli M;Puca L;Cyrta J;Marotz C;Giannopoulou E;Chakravarthi BV;Varambally S;Tomlins SA;Nanus DM;Tagawa ST;Van Allen EM;Elemento O;Sboner A;Garraway LA;Rubin MA;Demichelis F
通讯作者：
Demichelis F
影响因子：
64.5
作者：
Cancer Genome Atlas Research Network
通讯作者：
Cancer Genome Atlas Research Network
DOI：
10.1158/1078-0432.ccr-15-0137
发表时间：
2016-03-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Beltran H;Jendrisak A;Landers M;Mosquera JM;Kossai M;Louw J;Krupa R;Graf RP;Schreiber NA;Nanus DM;Tagawa ST;Marrinucci D;Dittamore R;Scher HI
通讯作者：
Scher HI
影响因子：
11.5
作者：
Chakraborty, Goutam;Armenia, Joshua;Kantoff, Philip W.
通讯作者：
Kantoff, Philip W.